Shih is also an investigator at the Innovative Genomics Institute (IGI) at UC Berkeley. "The current plant transformation ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

CAGR offers a clear view of long-term investment trends by balancing fluctuations for a steady growth rate. BCC Research ...

For some autistic people, assistive technology can improve certain abilities. For others, it can enable them to do things they may not have been able to before. This article covers the ways assistive ...

The efficiency of the CINV-mediated delivery of plasmid DNA encoding EGFP varied depending on the type of recipient cells. Surprisingly, under experimental conditions, CINVs were unable to deliver ...

Members of the team had previously reported that P. rustigianii carries a cytolethal distending toxin virulence gene on its plasmid. Elimination of this gene did not reduce the bacteria's ...

Scientists have identified a new virulence gene from a whole genome analysis of Providencia rustigianii, which can cause severe food poisoning symptoms. Members of the team had previously reported ...

Pharmaceutical drug dosage forms are traditionally determined through extensive physical experimentation. Here, the authors present a generative AI method that creates digital drug products from ...